Search clinical trials for: Sitagliptin placebo

Total 53952 results

Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
Emory University
Merck Sharp & Dohme LLC

Terminated

DPP-4 Inhibition and TZD for DM Prevention (DInT DM)

Prediabetic State

United States
AstraZeneca

Completed

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (MEASURE-HF)

Heart Failure | Type 2 Diabetes Mellitus

United States, Thailand, Korea, Republic of, Russian Federation, Ukraine, Hungary, Bulgaria, Chile, Canada, Romania
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
University of Sao Paulo General Hospital
InCor Heart Institute

Completed

DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function

Platelet Aggregation During Acute Myocardial Infarction

Brazil
AstraZeneca
Bristol-Myers Squibb

Completed

18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

Type 2 Diabetes

Mexico, South Africa, Norway, Argentina, Belgium, Denmark, Sweden, France, Italy
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
University Hospital Inselspital, Berne
Fresenius Kabi

Completed

The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies (Glutaminprojec)

Malnourishment | Gastrointestinal Tumors

Switzerland
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
University of Colorado, Denver
Merck Sharp & Dohme LLC

Completed

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Cardiovascular Disease | Type 2 Diabetes

United States
Lundquist Institute for Biomedical Innovation at...
Emmaus Medical, Inc.

Terminated

L-Glutamine Therapy for Sickle Cell Anemia

Sickle Cell Anemia | Thalassemia

United States
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Eurofarma Laboratorios S.A.

Completed

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) (EVOLUTION)

Diabetes Mellitus, Type 2

Brazil
Shanghai Jiao Tong University School of Medicine

Unknown

Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Type 2 Diabetes

China
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Sitagliptin for Reducing Inflammation and Immune Activation

HIV-1 Infection

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion (INDORSE)

Type 2 Diabetes

Canada
NeuroBo Pharmaceuticals Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NON-ALCOHOLIC STEATOHEPATITIS

United States
Novo Nordisk A/S

Completed

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes (PIONEER 12)

Diabetes Mellitus, Type 2

Serbia, South Africa, Taiwan, Romania, Algeria, Hong Kong, Brazil, China, Czechia
Lin Liao

Unknown

Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin

Type 2 Diabetes Mellitus

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)

Diabetes Mellitus, Type 2 | Chronic Renal Insufficiency
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (SUSTAIN)

Diabetes Mellitus, Type 2 | Diabetes

Taiwan, Korea, Republic of, South Africa, Hong Kong, Brazil, China, Ukraine
Lund University

Completed

Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes

Type 2 Diabetes

Sweden
Takeda

Terminated

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Ukraine, Poland, Malaysia, Canada, Peru, Philippines, Hungary, Russian Federation, South Africa, Argentina, Croatia, Thailand
Lund University

Completed

DPP-4 Inhibition, Incretins and Islet Function (CODI24)

Type 2 Diabetes

Sweden
Theracos

Completed

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Type 2 Diabetes Mellitus

United States, Japan, Czechia, Hungary, Poland, Spain
The University of Texas Health Science Center at...

Completed

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM

Diabetes

United States
Amsterdam UMC, location VUmc
EU FP7: SAFEGUARD consortium

Completed

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Type 2 Diabetes

Netherlands
National Institute on Aging (NIA)

Completed

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Healthy Volunteers

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
University College Dublin

Completed

Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. (DIP)

Type 2 Diabetes Mellitus | Psoriasis

Ireland
Merck Sharp & Dohme LLC

Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
Merck Sharp & Dohme LLC

Completed

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Type 2 Diabetes Mellitus (T2DM)
Korea University Anam Hospital
AstraZeneca

Unknown

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Diabetes Mellitus, Type II

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Diabetes Mellitus, Non-Insulin-Dependent
University of Vermont
Merck Sharp & Dohme LLC

Unknown

Bone Turnover in Type 2 Diabetes Patients

Type 2 Diabetes

United States
GWT-TUD GmbH

Terminated

Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus Type 2

Germany
St. Jude Children's Research Hospital
Thrasher Research Fund

Terminated

Trial of Oral Glutamine in Patients With Sickle Cell Anemia

Anemia, Sickle Cell

United States
Merck Sharp & Dohme LLC

Completed

A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

Type II Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Type 2 Diabetes Mellitus
Hoffmann-La Roche

Completed

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Diabetes Mellitus Type 2

United States, France, Switzerland, Germany, South Africa, Korea, Republic of, Puerto Rico, Canada, Taiwan, Spain, Poland, Slovakia, Thailand, Mexico, Turkey, Australia, Greece, Norway, Sweden, Peru, Romania, Argentina, United Kingdom
University of Arkansas

Terminated

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

Breast Cancer

United States
University at Buffalo

Withdrawn

Sitagliptin in Type I Diabetic Patients

Diabetes Type I

United States

3

Subscribe